Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.06 and traded as low as $0.06. Nascent Biotech shares last traded at $0.06, with a volume of 41,000 shares traded.
Nascent Biotech Trading Down 4.2 %
The company has a fifty day moving average of $0.06 and a 200-day moving average of $0.06.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Read More
- Five stocks we like better than Nascent Biotech
- P/E Ratio Calculation: How to Assess Stocks
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
